Patentability, Biosimilars Top Life Sciences Issues for 2012

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together.

January 13, 2012

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together, industry attorneys and executives told Bloomberg BNA during telephone interviews and e-mail exchanges in December.

They indicated that it could be a year when clarity about what is patentable subject matter is achieved from at least one and perhaps two Supreme Court rulings and when personalized medicine, which cuts across federal agencies, the private sector, and a number of other life sciences issues, could definitely become the focus of the industry. And it could be a year when implementing the abbreviated biosimilars approval pathway will result in stronger collaborations among biotechnology, pharmaceutical, and generic drug companies.

Reproduced with permission from Life Sciences Law & Industry Report, 6 LSLR 47 (Jan. 13, 2012). Copyright 2012 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com

Related Publications

November 2020
Explaining the Almost Unexplainable
David Prange, Benjamen Linden, Vivek Biswas - Intellectual Property Magazine
November 9, 2020
Hatch-Waxman Venue Is Further Narrowed
Jeffrey Alan Hovden, Haroon Mian
Winter 2020
Embracing the New Normal: Tips for Remote Depositions
Erica Ramsey - The Robins Kaplan Insurance Insight: Winter 2020
Winter 2020
The Import of Authentic Leadership – Especially In Times of Crisis
Melissa M. D’Alelio - The Robins Kaplan Insurance Insight: Winter 2020
Back to Top